AGREEMENT
THIS AGREEMENT (this "AGREEMENT") is entered into by and between
Halifax Fund, L.P. (the "STOCKHOLDER") and ChromaVision Medical Systems, Inc.
(the "COMPANY") this ____ day of February, 2002, with reference to the following
facts:
A. The Stockholder currently holds shares of Series D 5% Cumulative
Convertible Preferred Stock of the Company (the "SERIES D PREFERRED"), purchased
from the Company in a private placement on July 10, 2001 (the "CLOSING DATE").
B. Pursuant to the Certificate of Designations relating to the Series D
Preferred (the "CERTIFICATE"), the holders of Series D Preferred are entitled to
vote as a single class along with the holders of Common Stock of the Company,
with each holder of Series D Preferred entitled to one vote for each share of
Common Stock into which such holder's shares of Series D Preferred are then
convertible.
C. The price at which shares of Series D Preferred were convertible
into shares of Common Stock at the time of issuance was $6.5746 per share. Under
the terms of the Series D Preferred the conversion price is to be adjusted on
July 10, 2002 to a price based upon an average of trading prices of the
Company's Common Stock at that time but in no event is the adjusted price to be
greater than the initial conversion price or less than $4.0019 per share (the
"CONVERSION ADJUSTMENT"). If the Conversion Adjustment occurs, the Series D
Preferred may become convertible into additional shares of Common Stock (the
"ADDITIONAL SHARES"), which would increase the voting power of the holders of
the Series D Preferred with respect to any matters on which such holders vote as
a single class along with the holders of Common Stock.
D. The staff of the Nasdaq Stock Market, Inc. ("NASDAQ") has questioned
whether the Conversion Adjustment is consistent with Nasdaq's voting rights
policy.
E. The Stockholder and the Company desire to enter into this Agreement
providing that the Stockholder will not exercise any voting power based on the
Additional Shares to address the concern of the Nasdaq staff regarding that
issue.
NOW, THEREFORE, in consideration of the foregoing premises, and for
other good and valuable consideration, the receipt and sufficiency of which
hereby are acknowledged, the parties hereto agree as follows:
1. Voting of Additional Shares. Subject to Section 3 below, the Stockholder
hereby waives and agrees not to exercise its rights to vote the Series D
Preferred to the extent of any Additional Shares which may become issuable upon
conversion of such holder's Series D Preferred as a result of the Conversion
Adjustment; provided, however, that the foregoing waiver shall not affect or act
as a waiver of any other voting rights granted to holders of the Series D
Preferred in the Certificate that are not based on the Additional Shares.
2. Restrictions on Transfer. The Stockholder hereby agrees that it will not
sell, assign, transfer, pledge or dispose of any shares of Series D Preferred or
grant any proxy or enter into any arrangement by which another person or entity
has the power to vote shares of Series D
Preferred held by the Stockholder unless the purchaser, assignee, transferee,
pledgee or other person or entity agrees to be bound by the terms of this
Agreement by executing and delivering a copy hereof to the Company. The
Stockholder hereby consents to the inclusion of a legend on its stock
certificate(s) representing its Series D Preferred as follows:
THE VOTING RIGHTS ASSOCIATED WITH THE SHARES OF SERIES D PREFERRED
STOCK REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN
RESTRICTIONS SET FORTH IN AN AGREEMENT BETWEEN THE HOLDER HEREOF AND
THE COMPANY, COPIES OF WHICH ARE AVAILABLE UPON REQUEST FROM THE
COMPANY
3. Condition to Effectiveness. This Agreement shall not be effective unless and
until each other holder of Series D Preferred executes and delivers an agreement
in substantially the same form and with the same substance as this Agreement.
4. Miscellaneous. This Agreement shall be governed by and construed in
accordance with the law of the State of Delaware, without giving effect to its
conflicts or choice of law principles. This Agreement represents the complete
and final understanding of the parties hereto with respect to its subject matter
and supersedes any prior or contemporaneous oral or written agreements or
understandings with respect to such subject matter. This Agreement may not be
assigned by either party without the written consent of the other party, and
this Agreement shall be binding upon, and inure to the benefit of, each party
and their respective successors and permitted assigns. This Agreement may not be
supplemented or amended unless (i) such supplement or amendment is set forth in
a written instrument executed by both parties hereto, (ii) the agreements
executed by the other holders of Series D Preferred are similarly supplemented
or amended and (iii) the Company notifies the staff of the Nasdaq in writing of
the nature of the supplement or amendment.
[signature page follows]
2
IN WITNESS WHEREOF, the undersigned have executed this Agreement as of
the date first written above.
HALIFAX FUND, L.P.
By: /s/ Xxxxxxx Xxxxxxx
Name: Xxxxxxx Xxxxxxx
Title: Controller
CHROMAAVISION MEDICAL SYSTEMS, INC.
By: /s/ Xxxxx X'Xxxxx
Name: Xxxxx X'Xxxxx
Title: Executive Vice President and Chief
Financial Officer
3
SCHEDULE OF IDENTICAL DOCUMENTS OMITTED
ChromaVision Medical Systems, Inc. entered into Agreements identical to
the foregoing Agreement in all respects (except for the identity of the party)
with following named parties. These agreements have been omitted as exhibits to
the Annual Report on Form 10-K pursuant to Instruction 2 to paragraph (a)(4) of
Item 601 of Form S-K:
Marchall Capital Management, Inc.
Castle Creek Healthcare Partners LLC
CCL Fund, LLC
Velocity Investment Partners, Ltd.
Cartmore Enterprises, Inc.
Safeguard Delaware, Inc.
4
